Our vision is to advance drug discovery and precision medicine by developing innovative chemistry
Our mission is to transition scientists to superior fluorescent tools for robust, safe and sustainable biomedical research.
Our values
Our actions are guided by four values that shape how we work, with each other and with the scientists we serve.
Team
We are a diverse, respectful, and collaborative team. Our actions are guided by what benefits the team as a whole.
Rigorous innovation
We apply meticulous and disciplined methodologies to drive groundbreaking innovations in chemistry.
Courage
We embrace the most challenging scientific problems to find solutions that address the needs of our customers.
Trust
We diligently earn and maintain the trust of our customers and shareholders through consistent performance and integrity.
Our story
Born at the University of Santiago de Compostela
Celtarys was founded in 2021 as a spin-off from the University of Santiago de Compostela with a clear mission: to accelerate drug discovery through innovative fluorescence technologies that replace traditional radioactive assays.
From the beginning, we have focused on developing high-performance fluorescent chemical tools that enable researchers to study challenging biological targets with greater speed, safety, and precision. Today, our portfolio includes more than 40 fluorescent ligands used by researchers in over 14 countries, and our technology has been validated through strategic collaborations and competitive research funding.
Ready-to-use, for faster adoption
As we worked with researchers, we recognized that ease of use is just as important as performance. This led us to develop ready-to-use assay kits that combine our fluorescent tracers with optimized protocols and all the required components, making advanced assays faster and easier to implement.
Extending our innovation
Building on this foundation, Celtarys is now extending its innovation beyond research tools. Alongside the continued development of fluorescence-based assay solutions, we are advancing a proof of concept for a targeted protein degradation (TPD) candidate, leveraging our expertise to contribute directly to the discovery of next-generation therapeutics.
Reimagining the future for patients
We aim to achieve excellence in fluorescence-based solutions for drug discovery while translating scientific innovation into technologies and therapeutics that help bring better medicines to patients faster.
Founders: Prof. Eddy Sotelo, Jhonny Azuaje, PhD and Maria Majellaro, PhD
Our research, from scientists to scientists.
As scientists we understand the unmet research needs. With our collaborators we jointly identify opportunities for improvement in drug discovery.
